Form 4: Dianthus Therapeutics CEO Awarded Stock Options

Dianthus Therapeutics CEO Marino Garcia was granted stock options to purchase 340,000 shares of common stock on February 3, 2025.

Summary

• Marino Garcia, CEO and President of Dianthus Therapeutics, Inc., was granted stock options on February 3, 2025.
• The stock options allow Garcia to purchase 340,000 shares of Dianthus Therapeutics common stock at an exercise price of $22.07 per share.
• The options vest in equal monthly installments over four years, starting January 1, 2025, contingent upon Garcia's continued service to the company.
• The options expire on February 2, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral-positive event.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders. The size and terms of the grant are typical for a CEO of a publicly traded company in this sector.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule of four years with monthly installments is a common practice to ensure long-term commitment.
• The exercise price is typically set at or above the market price on the grant date, which appears to be the case here.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the CEO's interests with increasing shareholder value.
• Employees may see it as a sign of confidence in the company's future.

Key Dates